Abstract
Background
Statins may exert a protective effect against the risk of venous thrombosis (VT), but the mechanism is unclear.
Objectives
In this open‐label, randomized clinical trial (www.clinicaltrials.gov NCT01613794), we aimed to determine the ex vivo effect of rosuvastatin on platelet reactivity in patients with a history of VT.
Methods
Platelet reactivity, in platelet reaction units (PRUs), was measured at baseline and after 28 days with VerifyNow, which uses arachidonic acid to determine thromboxane‐mediated platelet aggregation, in 50 consecutive patients included in our study (25 receiving rosuvastatin and 25 without intervention).
Results
Forty‐seven of 50 (94.0%) consecutively enrolled patients had two valid PRU measurements. The mean PRUs in rosuvastatin users were 609 at baseline and 613 at the end of the study (mean change 5; 95% confidence interval [CI] − 18 to 27). The mean PRUs in non‐users were 620 at baseline and 618 at the end of the study (mean change − 2; 95% CI − 15 to 12). The mean difference in PRU change between users and non‐users was 6 (95% CI − 20 to 33). After exclusion of patients who used antiplatelet medication, or had thrombocytopenia, similar results were obtained, i.e. no apparent effect of rosuvastatin on PRUs, with a mean difference in PRU change between users and non‐users of − 1 (95% CI − 20 to 19).
Conclusions
Rosuvastatin does not affect platelet reactivity when arachidonic acid is used as an agonist in patients with a history of VT
Statins may exert a protective effect against the risk of venous thrombosis (VT), but the mechanism is unclear.
Objectives
In this open‐label, randomized clinical trial (www.clinicaltrials.gov NCT01613794), we aimed to determine the ex vivo effect of rosuvastatin on platelet reactivity in patients with a history of VT.
Methods
Platelet reactivity, in platelet reaction units (PRUs), was measured at baseline and after 28 days with VerifyNow, which uses arachidonic acid to determine thromboxane‐mediated platelet aggregation, in 50 consecutive patients included in our study (25 receiving rosuvastatin and 25 without intervention).
Results
Forty‐seven of 50 (94.0%) consecutively enrolled patients had two valid PRU measurements. The mean PRUs in rosuvastatin users were 609 at baseline and 613 at the end of the study (mean change 5; 95% confidence interval [CI] − 18 to 27). The mean PRUs in non‐users were 620 at baseline and 618 at the end of the study (mean change − 2; 95% CI − 15 to 12). The mean difference in PRU change between users and non‐users was 6 (95% CI − 20 to 33). After exclusion of patients who used antiplatelet medication, or had thrombocytopenia, similar results were obtained, i.e. no apparent effect of rosuvastatin on PRUs, with a mean difference in PRU change between users and non‐users of − 1 (95% CI − 20 to 19).
Conclusions
Rosuvastatin does not affect platelet reactivity when arachidonic acid is used as an agonist in patients with a history of VT
| Original language | English |
|---|---|
| Pages (from-to) | 1404-1409 |
| Number of pages | 6 |
| Journal | Journal of Thrombosis and Haemostasis |
| Volume | 14 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 2016 |
Keywords
- blood platelets
- hydroxymethylglutaryl-CoA reductase inhibitors
- platelet function test
- randomized clinical trial
- venous thrombosis